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SUMMARY  
 
Objectives: The aim of this study was to determine the prevalence and type of human 
papillomavirus (HPV) in various oral lesions in comparison to control healthy oral mucosa, and 
the dynamic of HPV infection course (persistence, change of HPV type and clearance).  
Material and Methods: The study comprised 426 consented subjects, of which 343 patients 
with different oral lesions and 83 controls with apparently healthy oral mucosa, referred for oral 
examination in the period from 2000 to 2015.  The diagnoses of oral lesions were established 
according to clinical criteria and confirmed by histopathology. Oral cytobrush samples were 
collected from oral lesions and healthy mucosa from different topographic sites and the HPV 
types were determined by polymerase chain reaction (PCR). The presence of HPV DNA was 
evaluated by consensus and type-specific (TS) primer-directed PCR. A subset of samples was 
analysed for the presence of both alpha and beta genus HPV types. 
Results: Out of 426 specimens, 144 (41.98%) from oral lesions and 15 (18.07%) controls were 
positive for HPV DNA; 22.3% of all tested samples contained beta-HPV type and 15.02% 
alpha-PV type. The highest prevalence of beta-HPV and high risk (HR) HPV (alpha-HPV) 
types were found in benign and premalignant oral lesions, while HR-HPVs were found in a 
small number of control samples. In 38 subjects sampling was performed more than twice, in 
average 2.29 times, with time distance between sampling of 5.8 months. Twenty-six of these 
38 patients were continuously HPV negative, five had transient infection, five acquired a new 
HPV infection, one had persistent HPV infection, and one had initially co-infection with 
different HPV types followed with new one during which initial oral lesion became malignant. 
The topographic distribution of the alpha-PV and beta-PV types showed affinity for the anterior 
part of the oral cavity and particular risk localization.  
Conclusion: Positive finding of HPV in all age groups and on healthy oral mucosa, high 
prevalence of HPV types in oral premalignant and proliferative lesions, affinity for risk 
localization in the oral cavity, unpredictable dynamic course and change of HPV type indicates 
the need for regular oral assessment and HPV control in patients with initially positive findings 
on oral mucosa. 
 
Keywords: Oral cavity, benign oral lesions, premalignant oral disorders, oral cancer, human 
papillomaviruses (HPV), alpha-PV type, beta-PV type 
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SAŽETAK 
Uloga humanih papiloma virusa (HPV) u razvoju dobroćudnih i zloćudnih promjena  
sluznice usne šupljine 
Cilj istraživanja bio je ispitati prevalenciju i tip humanog papiloma virusa (HPV) u različitim 
oralnim lezijama u usporedbi s kontrolnom, naizgled zdravom sluznicom i dinamiku tijeka HPV 
infekcije u ustima (ustrajnost, promjenu tipa HPV i prolaznost infekcije). 
Ispitanici i postupci: U ispitivanju je sudjelovalo 426 ispitanika, od kojih 343 bolesnika s 
različitim oralnim lezijama i 83 kontrolnih s naizgled zdravom sluznicom koji su upućeni na 
pregled usne šupljine u razdoblju od 2000. do 2015.godine. Svi ispitanici dali su svoj 
informirani pristanak prije uključivanja u ovo istraživanje. Dijagnoze oralnih lezija postavljene 
su na temelju kliničkih kriterija i potvrđene histopatološkom analizom. Citološki obrisci uzeti 
su citološkom četkicom s oralnih lezija i zdrave sluznice s topografski različitih mjesta sluznice, 
a HPV je dokazan lančanom reakcijom polimerazom (PCR). Prisutnost HPV DNA dokazana je 
PCR-om sa zajedničkim i tip-specifičnim početnicama. Određeni dio uzoraka bio je testiran na 
tipove HPV-a iz roda alfa i beta.  
Rezultati:  U svih 426 testiranih uzoraka, HPV DNA dokazana je u 144 (41,98%) uzoraka s  
oralnih lezija i 15 (18,07%) kontrolnih; 22,3% ispitanih uzoraka sadržavalo je  tip HPV iz roda 
beta, a 15,02% tip HPV iz roda alfa. Najveća prevalencija beta-HPV i visokorizičnih (HR) HPV 
tipova (alfa-HPV) pronađeni su u benignim i premalignim oralnim lezijama, a visokorizični 
HPV tipovi pronađeni su i u malom broju kontrolnih uzoraka. U 38 ispitanika uzorkovanje je 
provedeno više od dva puta, u prosjeku 2.29 puta, u vremenskom razmaku od prosječno 5,8 
mjeseci. Dvadesetšest od 38 ispitanika bilo je stalno negativno na HPV, u pet je dokazana 
prolazna infekcija, pet je steklo novu infekciju HPV-om, jedan ispitanik imao je stalnu infekciju 
HPV-om, a jedan je tijekom praćenja  početno dokazanu koinfekciju s različitim tipovima HPV-
a i stekao novu s HPV tipom visokog rizika tijekom koje je inicijalna premaligna lezija sluznice 
postala zloćudna.  Analiza topografske distribucije  alfa-HPV i beta-HPV tipova na oralnoj 
sluznici pokazala je afinitet virusa za sluznicu prednjeg dijela usne šupljine i osobito za rizične 
lokalizacije. 
Zaključak: Pozitivan nalaz HPV-a u svim dobnim skupinama i na  zdravoj sluznici te visoka 
prevalencija HPV tipova u oralnim premalignim i proliferativnim lezijama kao i afinitet za 
rizične lokalizacije te nepredvidljiv dinamičan tijek uz promjene tipa HPV-a upućuju na 
potrebu kontrole na HPV u kliničkoj stomatološkoj praksi kod inicijalno pozitivnog nalaza.      
Ključne riječi: usna šupljina, dobroćudne oralne lezije, premaligne lezije, rak usne šupljine, 
humani papilomavirusi (HPV), alfa-HPV, beta-HPV  
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LIST OF ABBREVIATIONS 
 
DNA - deoxyribonucleic acid 
E6 - early gene of HPV coding for the oncoprotein E6 
E7 - early gene of HPV coding for the oncoprotein E7 
HLA - human leukocyte antigen 
HPV - Human papillomavirus 
HR - high risk (HPV type) 
HSV - Herpes simplex virus  
LCR - long control region  
LR - low risk (HPV type) 
OLL - oral lichenoid lesions  
OLP - oral lichen planus 
p53 - tumour suppressor protein 53 
PCR - polymerase chain reaction 
RB - retinoblastoma protein, a tumour suppressor protein p53 
RNA -  ribonucleic acid 
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1.1. Human papillomavirus (HPV) 
Human papillomavirus (HPV) has a double-helical DNA genome and is taxonomically 
classified in a Papillomaviridae family (1). They were first discovered, isolated, and sequenced 
from cervical tumor specimens and have been attributed to be one of the important causative 
agents for the development of cervical cancer by zur Hausen et al. (2, 3, 4). For this discovery 
Professor zur Hausen received the Nobel Prize of Physiology and Medicine for the year 2008.  
HPV have strict tropism and infect either mucosa (alpha genus papillomaviruses) or skin (beta 
and gamma genus papillomaviruses). Genital HPV infections contribute to more than 99% of 
cases of cancer of the cervix (5), 97% of cancer cases of the anus (6), 70% of cancer cases of 
the vagina (7), 47% of cancer cases of the penis (8), 40% of cancer cases of the vulva (7) 47% 
of cancer cases of the oropharynx, and 11% of cancer cases of the oral cavity (9, 5). There are 
more than 200 HPV genotypes, of which approximately 40 types infect the anogenital and oral 
mucosa, whereas the others infect the skin (10, 11).  
Alpha-HPVs have historically been classified according to their oncogenic potential and 
clinical behavior into low-risk (LR) HPV types, which were rarely or if ever found in cancer, 
and high-risk (HR) or carcinogenic types (12, 13) which were often found in cancer. The most 
common HR HPVs, types 16 and 18, cause more than 70% of cervical cancers and other 
anogenital carcinomas in women (vulvar, vaginal, and anal carcinomas) and men (penile and 
anal carcinomas), as well as oropharyngeal tumors in both men and women (14). The more 
recent classification classifies HPV types as carcinogenic (HR types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59), probably carcinogenic (type 68), and possibly carcinogenic (types 26, 30, 
34, 53, 66, 67, 69, 70, 73, 82, 85, 97) (15- 17). 
In contrast with the HR types, the LR HPV types, notably types 6 and 11, cause almost all 
clinically visible benign lesions, that are genital warts (flat condyloma and condyloma 
acuminate) and laryngeal papilloma (15). Oral condyloma acuminate and oral squamous cell 
papilloma are mostly caused by alpha-HPV types 6 and 11, whereas oral verruca vulgaris is 
caused by beta-HPV types 2 and 4 (12). Focal epithelial hyperplasia of the oral mucosa (Heck 
disease) is more common among Eskimos and American Indians than in most other population 
groups in the world (18). This disease has nonpapillomatous but rather a papular appearance 
and does not undergo malignant transformation. Focal epithelial hyperplasia is particularly 
associated with alpha-HPV types 13 and 32, and the HPV prevalence varies from 7% to 36% 
(19,20). Laryngeal papillomatosis (also known as recurrent respiratory papillomatosis) is a rare 
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condition consisting of benign tumours of the larynx or other areas of the respiratory tract, 
which are caused by LR HPV types 6 and 11 (21). Because the disease is most commonly found 
in children, disease is probably acquired during vaginal childbirth from the HPV-infected 
mother. Without treatment, it is potentially fatal, as uncontrolled growths may obstruct the 
airway (21). 
1.2. HPV associated lesions of the oral mucosa  
HPV is considered to be associated with oral potentially malignant disorders (OPMDs) such as 
oral leukoplakia, oral lichen planus, and erythroplakia (22, 23).  
Leukoplakia is the most common premalignant oral lesion with dysplasia, present in 5% to 25% 
of biopsies (24). Studies using polymerase chain reaction (PCR) (25) and genotyping have 
detected LR, HR, and multiple type HPV infections in oral leukoplakia (26,27). Dysplastic 
leukoplakias (26.2%) (28) are more likely than normal mucosa (10-13%) (28,29) to be infected 
with HPV. However, studies showing that oral precancerous lesions have a low viral load and 
that viral integration seldom occurs (30) strongly suggest that the virus is often there as a 
passenger (31) having little role in neoplastic transformation of these lesions.  
In the study of Szarka et al. (32) HPV was detected more frequently in OPMDs lesions than in 
controls, and the HPV prevalence rate increased gradually with the severity of the lesions, from 
32.8, 40.9 to 47.7% in oral lichen planus, oral leukoplakia, and oral squamous cell carcinoma 
(OSCC), respectively. Both LR and HR HPV types can be found in potentially malignant oral 
disorders (33) although only HR HPVs will lead to cancer. 
Erythroplakia is a lesion with the highest potential for malignant transformation (34). Nielson 
et al. (35) found HPV in 50% of the erythroplakias alone, whereas the overall HPV detection 
rate of all premalignant lesions (erythroplakias, homogenous leukoplakias, nodular and 
verrucous leukoplakias) including erythroplakias was 40.8%. Although the role of HPV causing 
cervical cancer is well established yet controversy surrounds regarding their role in 
oropharyngeal malignant and premalignant lesions and has attracted the researches throughout 
the world (7, 8, 9, 36). 
Infection of cervical epithelium with specific HR HPV types plays a fundamental role in the 
development of cervical cancer, by causing precursor lesions and maintaining malignant growth 
(37). Two review articles indicated that a similar mechanism is seen in oral potentially 
malignant disorders (38, 39). The first evidence of HPV association with OSCC (40) appeared 
  
4 
 
in 1983, revealing that about 61,500 oropharyngeal cancers, associated with HPV infection, 
which includes lingual cancer, tonsil cancer, and oropharyngeal cancer, occurred globally (41). 
These cancers were much more common in men (48,900 cases) than in women (12,600 cases). 
HPV-positive oropharyngeal cancers are associated with oral sex, age younger than 60 years, 
infrequent p53 gene mutation, and a more favourable clinical outcome, whereas HPV-negative 
cancers are associated with smoking, excessive alcohol use, age older than 60 years, frequent 
p53 gene mutation, and poor prognosis (42). HPV contributes to 47% of oropharyngeal cancers 
and 11% of oral cancers where HPV 16 was most commonly found in oropharyngeal (90%) 
and oral (96%) cancers (9). 
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1.2.1. Oral precancerous lesions and cancer 
The clear association between HPV and cervical cancer is not as strong for OSCC. Numerous 
studies have examined the relationship between HPV and oral squamous cell carcinoma OSCC 
(38-40). HPV integration into host DNA is less common in OSCC (39, 40). Kreimer et al. (41) 
found the prevalence of HPV to be 24% while Leemans et al. (42) found 35% in OSCC. Based 
on the latest review study of Gupta & Gupta (22) that included 50 studies on HPV prevalence 
in OSCC, oral lichen planus, verrucous carcinoma, oral leukoplakia, and benign and malignant 
papillary lesions during the period of 1994-2014, the frequency of HPV in OSCC varied from 
0% to 80%. The HPV type most commonly detected in OSCC and OPMDs were HPV 16 and 
18. HPV type 6 and 11 were mostly found in oral benign lesions and papilloma (43, 44, 45). 
The possible variation could be attributed to difference in ethnicity, geographic locations to 
variations in methods used for detection of HPV (46). Oral leukoplakia is the most common 
premalignant lesion that occurs in the oral cavity (47), although the majority of oral leukoplakia 
would not develop into malignant tumour. In areas of the world where smokeless-tobacco use 
is common, there is higher prevalence. Moreover, leukoplakia is more likely to occur with 
increasing age (48). The rate of transformation of oral leukoplakia into oral squamous cell 
carcinoma (SCC) varies approximately from 0 to 20%, and this malignant transformation may 
take 1 to 30 years (49). The role of HPV 16 in the causation of oral leukoplakia is unclear 
although numerous studies indices a strong independent risk factor for oral leukoplakia (32, 50-
57).  
1.3. Progression of HPV-associated lesions, HPV persistence and clearance  
The normal oral mucosa may act as a reservoir for new HPV infections and/or as a source of 
recurring HPV-associated lesions. The prevalence of HPV in normal oral mucosa range from 
0.6% to 81% (36, 58, 59) whereas HPV is spread by skin-to-skin, skin-to-mucosa, and mucosa-
to-mucosa contact. Transmission of HPV infection may occur through sexual contact, 
autoinfection, and occasionally through perinatal transmission of the neonate during its passage 
through and infected birth canal of the mother (60). Oral HPV acquisition was found to be more 
positively associated with number of recent oral sex and open mouth kissing partners than with 
the number of vaginal sex partners (58, 59).  
HPV infections are generally transient, with 60 to 70% of new infections clearing within 1 year 
and 91% clearing within 2 years (61). Only a small proportion of HPV infections progress to 
persistent infection, often involving HR HPV types that have been shown to persist longer than 
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LR HPV types (61). Cervical cancer precursor lesions persist longer and progress more quickly 
in women with HPV 16 and/or 18 infections than in women with other HR HV types and LR 
HPV types (12). HPV 16- and HPV 18-positive women have 200-fold increased risk for 
cervical cancer (62, 63). Factors that may influence progression include coinfection with other 
sexually transmitted infections such as Chlamydia trachomatis, herpes simplex virus (HSV) or 
human immunodeficiency virus (HIV), tobacco smoking, high parity  (more children) and 
immune suppression (64). The persistence of HPV infection is a major risk factor for 
carcinogenesis (65) with in addition chronic inflammation and bacterial coinfections that favor 
HPV infection (66). 
The HPV genome contains several early and late open reading frames coding for replication 
and transcription regulating proteins, E1, E2, E5, E6, E7 and viral capsid proteins, L1 and L2, 
respectively. Two early proteins, E6 and E7 act as a major viral oncoproteins, while the E5 acts 
as an auxiliary oncoprotein (12, 67). Both E6 and E7 are small proteins, approximately 18 and 
13 kDa in size, respectively, localized in the nucleus (68). The E6 proteins are also found in the 
cytoplasm and the E7 probably also has cytoplasmic component (69). The expression of the HR 
E7 proteins by themselves can immortalize human keratinocytes at a low frequency but E6 has 
no such activity. The combination of E6 and E7, however, is highly efficient at transforming 
and immortalizing most types of primary cells (70). In addition to E6 and E7, the E5 
oncoprotein plays an auxiliary role in cell transformation. Both HR and LR HPV oncoproteins 
bind their target proteins but HR do it with higher affinity and in addition often degrade them 
unlike to LR HPV oncoproteins (71). 
The transforming properties of HPV oncoproteins lie in the interaction with numerous host cell 
proteins resulting in the maintenance and the re-entering into the cell cycle, which consequently 
allows the virus to replicate as it is dependent on the host cell DNA replication machinery. In 
addition, the E7 protein, together with the E6 oncoprotein of the HR HPV types, is able to 
interfere with key cellular processes, such as cell cycle, senescence, differentiation, apoptosis 
and telomere shortening. Furthermore, because of the frequent integration of the HR HPV 
genome into a host cell chromosome, those two proteins are the only viral proteins that are 
consistently expressed in HPV associated cancers (16). The HPV E6 and E7 proteins also 
associate with enzymes that modulate histone acetylation and thus, broadly regulate the 
transcriptional competence of host cell chromatin (72). 
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This study is the continuation of our previous study shown in the master’s degree thesis 
defended in April 2008 and partially published (36).  
Herein, we show the findings of the follow-up of our patients including new cases to get a better 
insight into the dynamics of the course of HPV infection on oral mucosa and its association and 
influence on the course of particular oral lesions. 
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This study is a continuation of longitudinal research on oral lesions, which began in 1995. The 
aim of the study was to monitor the prevalence and the natural history of HPV infection in oral 
cavity associated with oral lesions.  
In our preliminary published results (36) we have shown that HPV DNA positive finding in 
oral cavity is linked predominantly to particular anatomical sites rather than the diagnosis itself 
indicating that topography plays an important role in HPV prevalence findings in oral mucosa 
and oral lesions.   
Herein, in the period from 2000 to 2015 we continued to follow-up our patients and included 
new ones in this study, in order to get a better insight into the dynamics of the course of HPV 
infection on the oral mucosa and its association and influence on the course of particular oral 
lesions. 
Thus, the specific objectives of this study were to determine: 
- the prevalence of different HPV types in different oral lesions in the cohort of oral 
medicine patients in comparison to controls with healthy oral mucosa,  
- whether the oral HPV infections are transient or permanent,  
- whether the HPV-associated lesions progress to a more severe form of disease,  
- whether during the follow-up of HPV infection on oral mucosa, the type of virus 
changes,  
- the distribution of alpha-HPV and beta-HPV types on oral mucosa and its prognostic 
significance, and finally 
- the risk of the oral HPV infection in order to assess the need for regular monitoring for 
oral cavity. 
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3.1. Study population  
The study comprised 426 subjects of which 343 patients with oral mucosal lesions (test group) 
and 83 controls with apparently healthy oral mucosa. The test group consisted of 275 women 
(aged 4-83 years) and 151 males (aged 4-82 years). The average age of all subjects was 46.46 
years (Table 1). All included subjects were referred for oral examination to the Department of 
Oral Medicine, School of Dental Medicine, University of Zagreb and assessment was 
performed in the period from 2000 to 2015. 
As this study builds upon our earlier longitudinal research on the role of HPV in the oral cavity 
and the observation HPV natural history in association with oral lesions, it included the 
individuals of our previous report (36). We continued to follow up these patients and included 
new to 2015, with regard to their clinical diagnoses and HPV presence in order to get insight 
into the dynamics of the course of HPV infection on oral mucosa and its association with the 
course of oral lesions.  
Inclusion criteria for all patients were:   
 their written consent to participate in this research  
 the presence of oral lesion suspected to be associated with HPV infection  
 oral lesions with increased risk of malignant change 
 lack of knowledge of present or previous HPV infection anywhere in the body 
Exclusion criteria were:   
 that patients were under immunosuppressive therapy at the time of sampling. 
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3.1.1. Ethic statement 
Before the year 2001 verbal patient consent was obtained at the time of sample collection, and 
since then, written informed consent has been obtained from the participants. All relevant 
patient data (anamnestic, clinical diagnosis), the DNA extracted from oral specimens and HPV 
testing results were processed anonymously. HPV testing was done on demand through 
Laboratory service request forms, which had to be signed and stamped by the practicing oral 
medicine specialist, and approved by the Ruđer Bošković Institute of Zagreb. The whole study 
was approved by the Ethical Board, School of Dental Medicine, University of Zagreb in line 
with the Helsinki declaration. 
Consent patients and controls were included into the study in order as they came for clinical 
examination. In all patients, clinical diagnoses were established based on the medical history, 
physical examination and routine oral tests.  
Clinical diagnosis for oral premalignant lesions were further confirmed by histopathology (23). 
Repeatedly toluidine positive ulcerous lesions were also subjected to biopsy and histologically 
analysed.  
3.2. Patient samples 
From all consent 343 patients with oral lesions and 83 consent controls, oral scraping samples 
taken by cytobrush (Medscand AB, Sweden) were collected from various topographic sites and 
labelled according to the scheme WHO as described previously (36). A cytobrush was used for 
taking scraping at the site of clinically visible lesion, which were classified by clinical 
diagnosis, and from healthy mucosa in controls as well.  
Cytological samples were taken from clinically distinct oral lesions (potentially malignant 
lesions: 34.27% benign lesions, 23.24% inflammatory lesions 9.86% ulcerations 6.81% salivary 
gland diseases 4.93% and oral carcinoma 1.41% collected during oral examination at the 
Department of Oral Medicine, School of Dental Medicine, University of Zagreb. Control 
samples (n=83) with apparently healthy mucosa were also collected and analysed.  
Cytobrush samples from oral mucosa were immediately immersed in an Eppendorf conical 
tubes filled with 1.5 ml of sterile buffer for extraction (10 mM Tris pH 7.5, 1 mM EDTA pH 
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scraping were lysed. By the time of transport to the laboratory of the Department of Molecular 
Medicine, RBI, samples were stored in a freezer at -20°C for HPV detection and genotyping. 
3.3. Oral topography 
The topography of the oral mucosa is coded according to the modified WHO oral topography 
codes by Roed-Petersen and Roenstrup (Kramer et al 1980; Mattila et al 2012)(36) vermilion 
border - upper (13), lower (14), labial commissures - right (15), left (16), labial mucosa - upper 
(17), lower (18), labial sulci - upper (21), lower (22), cheek (buccal mucosa) - right (19), left 
(20), buccal sulcus - right upper (23) lower (24), buccal sulcus – left upper (25) lower (26), 
upper gingiva or edentulous alveolar ridge buccally - right (27), left (28), lower gingiva or 
edentulous alveolar ridge - right (29), left (30), upper anterior gingiva and edentulous ridge 
labially (31), lower anterior gingiva or edentulous ridge labially (32), upper posterior gingiva 
or edentulous alveolar ridge palatally - right (33), left (34), lower posterior gingiva or 
edentulous alveolar ridge lingually - right (35), left (36), anterior gingiva or edentulous ridge 
palatally (37), and lingually (38), dorsum of the tongue - right (39), left (40), base of the tongue 
- right (41), left (42), tip of the tongue (43), margin of the tongue - right (44), left (45), surface 
of the tongue - right (46), left (47), frontal floor of mouth (48), lateral floor of mouth - right 
(49), left (50), hard palate - right (51), left (52), soft palate - right (53), left (54), anterior tonsillar 
pillar - right (55), left (56). For regions with less than 3 samples analysed the frequency was 
not calculated; symmetrical regions were counted as one for the analysis. 
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Figure 1. Modified WHO oral topography codes by Roed-Petersen and Roenstrup  
(Kramer et al 1980; Mattila et al 2012) (36) 
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3.4. HPV detection and genotyping 
Samples were collected in TES buffer (10 mM Tris-HCl; pH 7.5, 1 mM EDTA, pH 7.9; 0.5% 
SDS), frozen at -20°C, and transported to the laboratory for HPV detection and genotyping. 
DNA was isolated by the high salt method which allows the precipitation of proteins. Briefly, 
oral cell suspensions were treated with proteinase K (100 µg/ml) in TES buffer overnight at 
37°C or 2 h at 56°C. Then, 1/3 volume of 5 M NaCl was added to the suspension, after 15-30 
min incubation at 4°C, and 15 min centrifugation at 4°C, and 14,000g, the supernatant was 
carefully collected, and treated with 2 volumes of 96% cold (-20°C) ethanol. The precipitation 
of DNA was facilitated by incubation for at least 2 hours at -20°C, and 15 min at -70°C. The 
DNA was then collected after 15 min centrifugation at 4°C, and 14,000 g, one washing of excess 
salt, and a second short centrifugation, and resuspended in ultra pure sterile water (50-100µl). 
The quality and quantity of DNA was determined spectrophotometrically (73). 
Alpha-PV detection by in-house polymerase chain reactions (PCR)  
Detection and genotyping of alpha genus HPV types was done as described previously (36). 
In house polymerase chain reaction (PCR) were performed using MY09/11 or PGMY09/11 
consensus PCR primers followed by type-specific PCR amplifying HPV types 6/11, 16, 18, 31, 
33, 45, 52, and 58 in 4 separate multiplex reactions for all samples irrespective of the initial 
consensus PCR results. Negative or very weakly positive samples by MY/PGMY09/11 and 
type-specific PCR were further analysed by L1C1/L1C2-1/L1C2-2, and/or GP5+/6+ consensus 
PCR. Human beta-globin was amplified together with the MY09/11 or PGMY09/11 consensus 
primers to verify the suitability of the isolated DNA for PCR. The PCR was performed with 5 
ng/µl of DNA in each reaction and each run included positive and negative controls (all reaction 
components except DNA). All standard procedures to avoid DNA contamination were applied.  
Beta-PV detection by Luminex  
The frequency of different beta/HPV types in cytobrush oral samples were detected by PCR 
amplification with FAP59/64 consensus primers (74). Furthermore, a subset of samples were 
additionally analysed for the presence of beta-PV types using type specific, multiplex genotying 
assay (TS-MPG assay, IARC, Lyon, France), which combines multiplex PCR with a bead-
based Luminex technology (75, 76). This assay detects 43 different beta-PV types, with the 
human beta-globin gene serving as a control. Each PCR amplification run included positive and 
negative controls and was set-up in dedicated clean box after UV light decontamination. 
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Following PCR, 10µl of each reaction mixture was analysed using the Luminex instrument 
(Luminex Corporation, Austin, TX) as described previously (77, 78) with additional assay 
negative control well. All runs were assessed for any repeat patterns of HPV positivity on 
individual run plates. 
3.5. Statistical data analysis 
Patient data was recorded in the MS Access database and analysed in MS Excel (Microsoft, 
USA). Chi square test and Chi2test for trend were used to determine statistically significant 
differences between sample groups and were calculated using Graph Pad Prism (GraphPad 
software, USA). P values < 0.05 were considered statistically significant. 
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4. RESULTS 
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4.1. Description of the study population 
In total, there were 343 subjects with oral diagnosis, and 83 control subjects with apparently 
clinically healthy oral mucosa (Table 1). Oral lesions were initially diagnosed according to 
clinical features and further confirmed by histopathology analysis. There were 275 women and 
151 men. The mean age of the study population was 46.46 years, ranging from 4 to 83 years. 
The mean age of control samples was 32.16 (15-70 years). 
 
         Table 1. Description of the study population  
Period of sample collection From January 13, 2000 to July 9, 2015 
Number of cases 
Oral mucosa changes 
Control* 
426 
343 
83 
Gender 
Women 
Men 
 
275 
151 
Age (mean age) 
Women 
Men 
from 4 to 83 (46.46) years 
from 4 to 83 (47.69) years 
from 4 to 82 (44.21) years 
*healthy oral mucosa 
 
Table 2 shows the distribution of individual clinical diagnosis grouped into six categories of 
diagnosis: 1) premalignant disorders (N=146); 2) benign proliferative lesions (N=99); 3) 
inflammatory lesions (N=42); 4) ulcerations (N=29); 5) salivary gland diseases (N=21) and 6) 
carcinoma (N=6). In majority of patients premalignant and benign oral lesions were present. 
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   Table 2. Frequency of individual clinical diagnosis distributed into the main categories  
Category of clinical diagnosis Patients % 
Premalignant 146 34.27 
Leukoplakia 73 17.13 
Lichen planus 54 12.67 
Lichen ruber erosivus 8 1.88 
Lichenoid reaction 6 1.41 
Erytroplakia 4 0.94 
Chelitis actinica 1 0.23 
Benign 99 23.24 
Papilloma 34 7.98 
Verruca vulgaris 28 6.45 
Keratosis mucosae 21 4.93 
Fibroma 12 2.81 
Hyperplasia mucosae 2 0.47 
Condyloma acuminata 1 0.23 
Solitary pigmentation  1 0.23 
Inflammatory 42 9.86 
Stomatitis 16 3.75 
Glossitis 14 3.28 
Chelitis 6 1.41 
Stomatitis nicotinica 3 0.70 
Candidosis 2 0.47 
Gingivitis 1 0.23 
Ulcerations 29 6.81 
Aphthae 11 2.58 
Decubital ulcerations 4 0.94 
Stomatitis ulcerosa 3 0.70 
Palatitis herpetica 2 0.47 
HSV gingivostomatitis 2 0.47 
Palatitis erosiva 2 0.47 
Herpes labialis 2 0.47 
Pemphigoid 1 0.23 
Gingivitis ulcerosa 1 0.23 
Herpangina 1 0.23 
Salivary gland diseases 21 4.93 
Sialoadenitis 14 3.28 
Mucocele 7 1.65 
Carcinoma 6 1.41 
OSCC 6 1.41 
Control 83 19.48 
Grand Total 426 100.00 
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Table 3 presents the distribution of oral diagnosis category according to gender. Women were 
twice more frequent than men and have twice more lesions in comparison to men. However, 
this finding cannot be interpreted as the women are twice as much sicker than men. Finding of 
increased incidence of oral cancer in men, compared to women, is consistent with 
epidemiological data (14).  
Table 3. Distribution of oral diagnosis by gender sorted descending by frequency  
Category of clinical 
diagnoses* 
Women Men Total 
N % N % N % 
232 67.64 111 32.36 343 80.52 
Premalignant 98 67.12 48 32.88 146 34.27 
Benign 68 68.69 31 31.31 99 23.24 
Inflammatory 31 73.81 11 26.19 42 9.86 
Ulcerations 18 62.07 11 37.93 29 6.81 
Salivary gland disease 16 76.19 5 23.81 21 4.93 
Carcinoma 1 16.67 5 83.33 6 1.41 
Control 43 51.81 40 48.19 83 19.48 
Total 275 64.55 151 35.45 426 100 
* Whenever patient had two or more diagnoses only the most severe diagnosis was taken into 
account for statistical analysis. 
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Figure 2 shows the distribution of oral diseases by age groups in all patients. The frequency of 
premalignant lesions increases with age. The occurrence of oral cancer is also more common 
in older age, while the occurrence of benign lesions decreases with age although their frequency 
is almost equal in all age groups.  
 
 
Figure 2. Distribution of oral diagnosis according to age groups  
(control = healthy oral mucosa) 
4.2. Oral sampling 
In 89.92% of subjects, including controls, samples from oral mucosa tested for the presence of 
HPV types were taken once, and in 10.08% subjects more than twice. In women samples were 
taken almost as much as in men, only in one man the sample was taken four times and in two 
women six times (Table 4). Multiple sampling was done with the purpose of monitoring 
dynamics of HPV infection. 
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    Table 4. Number of oral mucosa sampling per patient and according to gender. 
 
Sample 
taken 
F M 
 
Total examinees 
 
Total 
samples 
N % N % N % N 
Once 216 89.63 123 90.44 339 89.92 339 
Twice  22 9.13 12 8.82 34 9.02 68 
Three times 1 0.41 0 0 1 0.27 3 
Four times 0 0 1 0.74 1 0.27 4 
Six times 2 0.83 0 0 2 0.53 12 
Grand 
Total 
241 100 136 100 377 100 426 
 
 
 
   Table 5. The average number of sampling by groups of diagnoses for all subjects (patients 
        and controls) in which sample was taken once.  
 
Clinical oral diagnosis No of cases Average No of sampling 
Benign 99 1.12 
Carcinoma 6 1.33 
Control 83 1.04 
Inflammatory 42 1.02 
Premalignant 146 1.84 
Salivary gland disease 21 1.14 
Ulcerations 29 1.07 
Grand Total 426 1.34 
 
  
23 
 
The analysis of a sampling in both, patients and controls, shows that sampling was taken in all 
subjects on average 1.34 times, but most frequently in patients with premalignant lesions. In 
these patients, swabs were taken on average twice (Table 5). 
 
Table 6. Average number of sampling in all subjects according to the category of diagnosis 
                in which sample was taken more than two times (3x, 4x, and 6x).  
Clinical oral diagnosis No of cases Average No of sampling 
Benign 12 2 
Carcinoma 2 2 
Control 3 2 
Inflammatory 1 2 
Premalignant 64 2.92 
Salivary gland disease 3 2 
Ulcerations 2 2 
Grand Total 87 2.68 
 
The samples were taken in all subjects in average 2 times, while in 64 patients with 
premalignant lesions samples were taken almost 3 times (Table 6), what speaks in favor of 
regular control of these risk lesions (Table 6). 
4.3. HPV status in the core study population 
Prevalence of HPV infection in oral lesions and healthy oral mucosa is presented in Table 7.  A 
total of 426 samples from 343 patients and 83 controls collected during the period from 2000 
to 2015 were successfully analysed for the presence of HPV DNA. Positive finding HPV DNA 
was detected in 41.98% samples of oral lesions and in 18.07% control samples of healthy 
mucosa.  
There was a statistical difference in the presence of alpha HPV types* between oral 
premalignant changes and controls (p=0.0413) and between oral benign changes and controls 
(p=0.0008). There is also a statistical difference in the presence of beta HPV types** between 
oral premalignant changes and controls (p=0.0093) and between inflammatory lesions and 
controls (p=0.01).  
  
24 
 
In majority of lesions and in control samples beta-HPV undetermined type X was more 
prevalent than LR-HPV. In certain cases positive finding of HR HPV (alpha -HPV) was found 
predominantly in premalignant and benign proliferative lesions as well as in few cases of 
patients with ulcerations, salivary gland disease and inflammatory changes of oral mucosa and 
even in several controls (Figure 3).  
 
Table 7. HPV status in different oral diseases groups  
 
 
Positive 
Negative Total 
HPV 
Alpha 
HPV 
Beta HPV 
Total 
Positive 
  N % N % N % N % N % 
Oral diseases 59 17.2 85 24.78 144 41.98 199 58.02 343 80.52 
Premalignant 22 15.07* 39 26.71** 61 41.78 85 58.22 146 34.27 
Benign 24 24.24* 20 20.2 44 44.44 55 55.56 99 23.24 
Inflammatory 3 7.14 13 30.95** 16 38.1 26 61.9 42 9.86 
Ulcerations 4 13.79 5 17.24 9 31.03 20 68.97 29 6.81 
Salivary 
gland 
disease 
5 23.81 6 28.57 11 52.38 10 47.62 21 4.93 
Carcinoma 1 16.67 2 33.33 3 50 3 50 6 1.41 
Control 5 6.02* 10 12.05** 15 18.07 68 81.93 83 19.48 
Grand Total 64 15.02 95 22.3 159 37.32 267 62.68 426 100 
 
*    statistical difference in the presence of alpha HPV types 
**  statistical difference in the presence of beta HPV types 
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    Figure 3. Distribution of HPV risk groups according to oral diseases in HPV positive    
samples. HR - high risk (HPV 16, 18, 31, 33, 45, 52 and/or 58), LR - low risk (6 or 11) and 
X - HPV type(s) of undetermined risk, i.e. untyped HPV. 
 
The distribution of HPV types by age is shown in Figure 4. The frequency of beta HPV types 
prevail among all samples, increases with age and has a peak in middle and older age. However, 
in all age groups HR HPV (alpha -HPV) are present and are the most common between the ages 
of 20 and 30 years of age and over the age of 60. The reason for such distribution in younger 
patients can be sexual behaviour, and in the elderly decreased immunity and medications. 
Increased frequency of HR HPV types in the sixth and seventh decade of life correlates with 
greater appearance of premalignant oral lesions and cancer in these age groups as shown on 
Figure 4. 
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Figure 4. Distribution of HPV risk groups according to age groups; HR – high risk (HPV 16, 
18, 31, 33, 45, 52 and/or 58); LR - low risk (HPV 6 or 11); X - HPV type(s) of undetermined 
risk, i.e. untyped HPV. 
4.4. Subset of followed-up patients 
Through 15 years of monitoring of all subjects who participated in the study (from 2000-2015), 
in 38 patients oral mucosal samples assessed for HPV were taken more than twice. The reason 
for multiple sampling in addition to regular follow up of oral lesions, was also monitoring of 
dynamics of HPV infection in the oral mucosa with regard to the persistence of infection, 
change the type of the virus, the progression of lesions associated with virus type and clearance 
of HPV infection.  
Results has showed that out of the 26 initially HPV negative lesions, 5 became HPV positive: 
of these, infection with HR HPV 52 was proven in one case and in four cases with HPV X. 
Among five initially positive lesions, in one case the LR HPV 6/11 has been detected and in 
four cases HPV X, which cleared with time. Two cases that were initially negative, became 
positive during follow-up: one case with HPV X remained HPV X, while in another case of 
multiple HPV infection with HPV 6/11, 16 and 18, co-infection disappeared, and a novel 
infection with HPV 31 occurred. In this person during the follow-up period initial clinical 
premalignant lesion transformed to malignant change (Table 8).   
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Table 8. HPV status in followed-up patients with oral mucosa diagnosis 
 
Final Total 
Negative Positive  
Initial N % N % N % 
Negative 26 68.42 5* 13.16 31 81.58 
Positive 5** 13.16 2*** 5.26 7 18.42 
Total 31 81.58 7 18.42 38 100 
 
*one case with HR HPV 52 and 4 cases with HPV X, which occurred with time 
**one case with LR HPV 6/11 and 4 with HPV X, which cleared with time 
***in one case with HPV X remained HPV X, while in another case of multiple HPV infection 
with HPV 6/11, 16 and 18 resolved and a novel infection with HPV 31 occurred 
By analysing the course of HPV infection in patients with various oral lesions, greatest 
dynamics of HPV in benign and premalignant lesions was observed. Changes were seen in the 
a) shift of HPV types (after clearance of primarily infection with HPV 6/11, 16 and 18, new 
infection with type HPV 31 occurred); b) clearance of infection (with HPV X and HPV 6/11) 
in minority of cases; c) persistence of infection with the same type (HPV X and HR HPV52) 
and development of new infection with a new type (HPV X and HPV 31) as shown in Table 9. 
Table 9. Dynamic of HPV infection in followed-up patients with oral diseases  
HPV 
infection 
Transient 
Transient 
followed 
by new one 
New Persistant 
Continuously 
negative 
Total 
Inflammatory        0 0 0 0 1 1 
Salivary 
gland disease 
1* 0 0 0 0 1 
Ulcerations        0 0 0 0 1 1 
Benign 1 * 0 1* 1# 2 5 
Premalignant      3 *** 1** 2*  1* 20 27 
Carcinoma 0 0 1* 0 0 1 
Control 0 0 0 0 2 2 
Grand Total 5 1 4 2 26 38 
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* HPV X (different HPV types, other than 6/11, 16, 18, 31, 33, 45, 56 and 58)  
** same case primarily HPV 6/11, 16 and 18, then new infection with HPV 31  
***one case with HPV X and two cases with HPV 6/11 
#   one case with HR HPV 52 
 
 
Figure  5.  Follow-up of patients with oral mucosa changes and HPV status through years 
(green = negative HPV; red = positive HPV) with average infection time being 5.8 months 
(n=12; 2 cases permanently positive; five initially negative and became positive (-+), and five 
initially positive became negative (+-); outlier patient with 109 months between tests excluded). 
 
Figure 5 shows the timeline and dynamic course of HPV infection in twelve patients in which 
the sample was taken more tha two times during follow-up period. Four cases with premalignant 
changes acquired HPV infection, while in the three initially positive infection cleared. In one 
case of oral carcinoma, lesion was at first visit (before intervention) negative, and became 
positive on control sampling after intervention during follow up.  
4.5. HPV status according to oral topographical sites 
Table 9 and Figure 6 represent topographic distribution of HPV with particular attention to the 
distribution of alpha and beta genus HPV on oral mucosa irrespective of type of lesion. Each 
analysed sample had accompanying sampling location information according to the modified 
WHO oral topography coding (Table 10).  
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Table 10. Distribution of HPV according to WHO oral topography codes  
(by Roed-Petersen and Roenstrup (36). 
 
Region 
code 
(WHO) 
Location 
Total No. 
cases 
Alpha Beta 
No % No % 
13-18 Labial mucosa 49 12 24.5% 12 24.5% 
19-26 
Buccal and 
vestibular 
mucosa 
124 13 10.5% 27 21.8% 
27-38 Gingiva 48 5 10.4% 8 16.7% 
39-45 Tongue 72 13 18.1% 18 25.0% 
46-50 
Ventral tongue 
mucosa and 
sublingual 
mucosa 
46 10 21.7% 7 15.2% 
51-56 Palate 67 12 17.9% 11 16.4% 
whole Whole mucosa 35 7 20.0% 12 34.3% 
(blank) #N/A 154 20 13.0% 26 16.9% 
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Alpha HPV types 
 
Beta HPV types 
 
 
Figure 6. Distribution of HPV alpha and beta types in the oral cavity according to WHO 
oral topography codes (36) 
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Figure 6 graphically represents the distribution and frequency of alpha and beta genus HPV 
positivity at different topographical sites in the oral cavity. The affinity of a particular genus 
type HPV for certain topographical areas of the oral mucosa is observed. 
Alpha HPV types were found in the highest percentage in the anterior parts of the oral cavity: 
on the labial mucosa, commissure of the lips and vestibular oral mucosa, ventral tongue and 
sublingual mucosa. Such distribution of alpha HPV types show affinity for risk localizations in 
the mouth (commissure of the lips and ventral tongue and sublingual mucosa) and may have 
prognostic significance. 
Beta HPV types were in general more frequently detected compared to alpha types. They were 
found in wider areas of the oral cavity especially on the labial, buccal and vestibular mucosa 
including commissure of the lips, mucosa of the dorsum of the tongue and the lateral edges of 
the tongue where alpha HPV types are detected to a much lesser extent. 
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5. DISCUSSION 
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The association between HR HPV types and malignant lesions has been shown in many studies 
(4, 28, 29). HR HPV types are known to be potential etiologic factor in oral carcinoma and 
considered to be initiator epithelial proliferation (4). Although the association between 
anogenital HPV infections and anal and genital cancer is indisputable (12) yet controversy 
surrounds regarding their role in oropharingeal malignant and premalignant lesions (7-10). 
This study is the only study on both alpha- and beta-HPV type prevalence in oral mucosal 
lesions in the Croatian population and also the only one that was following HPV positive and 
negative lesions for a longer period of time in order to get better understanding of the 
relationship between HPV infection and different oral lesions. Although the collection of the 
study population took 16 years, the advantage of this study is its sample size and uniformity of 
material, sampling, and further processing procedures. All the oral scrapings were taken in the 
single clinic under the same conditions, and DNA preparation and HPV analysis was also done 
in the same manner in the research virological laboratory. Clinical diagnosis of the oral lesions 
and sampling was evaluated by a single specialist. In each case, oral epithelial cells were taken 
with the cytobrush and biopsies were excluded from this study. In addition, each specimen was 
classified according to the WHO topography code (79) in order to evaluate the relationship of 
HPV infection and oral lesions at the different locations of the mouth.  
Three sets of consensus primers were used to maximize the identification of alpha-HPV DNA. 
In addition, genotyping for specific alpha-HPV types was performed on all samples regardless 
of consensus PCR result to further increase the HPV detection sensitivity. Types selected for 
genotyping were chosen due to their abundance in cervical carcinoma in the world (65). Similar 
studies of HPV detection in oral cells by PCR were done earlier confirming the significant 
association of HPV positivity in oral carcinoma, potentially malignant disorders such as oral 
leukoplakia, oral lichen ruber planus, and epithelial dysplasia  
 
(38). This study includes all the listed oral lesions and only one lesion progressed in oral 
carcinoma. 
The HPV prevalence in healthy oral mucosa (n=15) and in oral lesions (n=144) is higher in men 
than in women both in our study and the literature (80, 81). However, regarding the different 
morphology and diagnosis, herein no statistically significant difference was found because of 
the low number of study subgroups.  
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As expected, we found statistical difference in the presence of alpha-HPV types between oral 
premalignant changes 15.07% and controls 6.02% (p=0.0413) and between oral benign changes 
24.24% and controls (p=0.0008). Furthermore, there was also statistical difference in the 
presence of beta-HPV types between oral premalignant changes 24.78% and controls 12.05% 
(p=0.0093) and between inflammatory lesions 30.95% and controls (p=0.01). These results 
suggest a significant association between the presence of premalignant oral lesions and benign 
(papilloma) and positive results for presence of oral HPV. Most of the studies that were 
investigating prevalence of HPV in oral lesions were focused on investigation of HPV 
prevalence in oral lesions that are known to be associated with HPV infection (oral papilloma, 
and precancerous and cancerous lesions) (27, 28, 33, 46).  In our study we included 
inflammatory disease and salivary gland diseases and we got significantly higher prevalence 
between these two groups compared with control group. One of the possible explanations for 
the observed data is that saliva play important role in behaviour of oral HPV infection. Reduced 
salivary flow makes oral mucosa more susceptible to micro trauma and infection (82) that is 
prerequisite for HPV infection.  
The prevalence of HPV infection in oral lesions in our study agrees with the findings of Miller 
and Johnstone (28) who found HPV infection rate two to three times higher in patients with 
precancerous oral lesions compared with healthy mucosa. Our results reinforce the hypothesis 
of possible causal role of HPV infection, especially HR HPV infection, in pathogenesis of some 
cases of oral premalignant lesions. The most common HPV type in premalignant oral lesion 
was HR HPV type that is similar to the results of other studies (22, 28, 32). Control samples of 
clinically healthy oral mucosa were HPV positive in 18.07% that is higher than results that 
Kreimer et al. (83). In their systemic review, they found 4.5% overall HPV positivity in healthy 
subjects, of which 1.3% had HPV 16. 
Based on our result HPV infection can affect any age group even though it seems to be most 
common between the age 20 and 30 years and over the age of 60. The reason for such 
distribution in younger patients can be sexual behaviour, and in the elderly decreased immunity 
and medications. Increased frequency of HR HPV types in the sixth and seventh decade of life 
correlates with greater appearance of premalignant oral lesions and cancer in these age group.  
Most of the infection were transient in our study that is similar to the findings on cervical 
epithelium (45); 60-70% of cervical infection clearing within 1 year and 91% clearing within 2 
years. HR HPV types have been shown to persist longer than LR HPV types (45). 
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Our results showed that topography plays a role in HPV prevalence in oral lesions. Even though 
the same lesions were found in different regions of the oral cavity, the HPV positivity was 
higher in specific topographical regions irrespective of diagnosis. It was not possible to analyse 
different diagnosis-topography combinations due to small sample subgroups, thus the data were 
grouped according to HPV frequency associated with the diagnosis and topography of lesions. 
The statistical analysis has shown that HPV positivity of the lesions that belong to the moderate 
or high HPV frequency-diagnosis subgroups is significantly associated with location. The 
topography was not significantly associated with low HPV frequency-diagnosis subgroup as 
the number of HPV positive samples was very small, but it was significantly associated with 
the moderate HPV frequency topography subgroup. Undoubtedly, it is true  
 
that some particular diagnoses are more associated with HPV and thus more often HPV 
positive, however, these data show that topography of the lesion is significantly associated to 
the HPV positivity of a particular lesion, and even somewhat more than the diagnosis. One of 
the possible explanations for the observed data is that the locations with the highest HPV 
positivity (vermilion border, labial mucosa and commissures, sublingual mucosa, ventrum of 
the tongue and lateral margins) are the most frequently exposed sites to micro trauma that is 
prerequisite for HPV infection transmission and these sites also pose the highest risk for 
malignant transformation.  
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6. CONCLUSION
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Based on the obtained result of the study we can conclude the following: 
 
1. the prevalence of different HPV types in different oral lesions in the cohort of oral 
medicine patients is significantly higher than in controls with healthy oral mucosa,  
2. oral HPV infection shows dynamic course and is transient in nature,  
3. premalignant HR HPV-associated lesion progressed to a more severe form of disease in 
one patient, 
4. during long term follow-up of HPV infection on oral mucosa, the types of HPV are often 
changing from one type to another, as shown in cases in which the primary infection 
was resolved and new one was acquired,  
5. the distribution of alpha-HPV and beta-HPV types on oral mucosa may have prognostic 
significance, since both HPV genus types affect mainly the mucosa of anterior parts of 
the mouth and HR HPV types of alpha genus has affinity for particular oral localizations 
which pose a risk for malignant transformation, 
6. the natural history of the oral HPV infection and its association with oral premalignant 
and proliferative lesions as shown in this study, indicates the need for regular oral 
assessment and HPV control in patients with initially positive findings on oral mucosa. 
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